Neos Therapeutics Receives Securities Complaint Over $40M Merger
Health your username February 4, 2021 A Neos Therapeutics, Inc. shareholder has filed suit against the company and its board of directors for violations of the Securities Exchange Act of 1934, arising from the board’s attempt to sell the company to Aytu BioScience, Inc. through its wholly-owned subsidiary Neutron Acquisition Sub, Inc (together, Aytu). The Southern District of New York complaint, filed on Wednesday, contends that the defendants filed a materially incomplete and misleading registration statement that must be amended in order for shareholders to make an informed decision about...
Source: lawstreetmedia.com